HCGExplore study findings
What a randomized trial found in patients with endometriosis and poor ovarian response
2 numbered sourcesSource years 2023, 2026
Peptides are short chains of amino acids joined by peptide bonds, and some carry hormonal signals. Human chorionic gonadotropin, abbreviated hCG, is a larger hormone built from two amino-acid chains with attached sugars. This makes it a glycoprotein. A 2026 trial asked whether adding a second hormone signal to a recombinant hCG trigger changed egg maturation in a defined group of fertility patients. [1, 2]
The participants had endometriosis and had met a study definition of poor ovarian response. They were undergoing intracytoplasmic sperm injection (ICSI), in which an embryologist places a sperm directly into a mature egg. Before retrieval, a trigger provides a signal for eggs to finish maturing. Both groups received recombinant hCG, which activates the same ovarian receptor as luteinizing hormone. One group also received a gonadotropin-releasing hormone agonist, which can prompt the pituitary gland to release its own hormones. The other group received a matching placebo for that additional intervention. [1, 2]
The researchers randomized 152 people. Of these, 128 completed the study protocol through embryo transfer. The primary endpoint was the number of eggs at metaphase II, the stage of maturity needed for ICSI. The group given both triggers had an average of about 6.5 mature eggs compared with about 4.1 in the hCG-only group. The authors also observed more top-graded embryos and higher clinical pregnancy rates in the group assigned both triggers. The trial distinguished outcomes among participants who completed the protocol from analyses that retained people according to their original group assignments. [1]
The endpoints occur at different stages. A mature egg can be fertilized but may never become a transferable embryo. An embryo can be transferred without producing an ongoing pregnancy, and a clinical pregnancy can end before live birth. The study measured egg and embryo outcomes and reported clinical pregnancy. Its findings cannot establish a live-birth advantage from the published outcomes. The result is also tied to the study's eligibility criteria, which selected for endometriosis and poor ovarian response. People with different diagnoses or different patterns of ovarian response might experience different results. [1]
The U.S. label for recombinant hCG covers specified fertility indications. The trial compared two approaches within a specific ICSI population and measured what adding the agonist changed in that setting. Its findings do not broaden the product's approval to every trigger combination or establish that the same comparison will give the same result in all fertility programs. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
